Etiology and disease process of benign prostatic hyperplasia

The Prostate

Volumn 15, Issue 2 S, 1989, Pages 33-50

  Isaacs, John T ^a   Coffey, Donald S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aging; natural history; prevalence

Indexed keywords

ADULT; AGE; AGED; CELL COUNT; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROSTATE; PROSTATE HYPERTROPHY; REVIEW; STEM CELL;

ADULT; AGE FACTORS; AGED; CELL COUNT; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATE; PROSTATIC HYPERPLASIA; STEM CELLS;

EID: 0024832529     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.2990150506     Document Type: Article

References (65)

1. Benign prostatic hyperplasia: Etiological considerations
2. Incidence of occult adenocarcinoma of the prostate
3. Benign hypertrophy of the prostate. A morphological study
4. Post‐natal changes in the human prostate
5. Benign nodular hyperplasia of the prostate: A review
6. Study of latent carcinoma of the prostate in Japanese based necropsy material
7. Morphogenesis of nodular hyperplasia‐prostate
8. Latent prostatic cancer in a consecutive autopsy series
9. Natural history of benign prostatic hypertrophy
10. The etiology of benign prostatic hypertrophy
11. Benign hypertrophy and carcinoma of the prostate
12. The development of human benign prostate hyperplasia with age
13. Benign prostatic hyperplasia treated by castration or LH‐RH analogue buserelin: A report of 6 cases
14. The effects of nafarelin acetate, a luteinizing hormone releasing hormone agonist, on benign prostatic hyperplasia
15. Origin and evaluation of benign prostatic enlargement
16. Incidence of prostatic enlargement among 6, 975 males
17. Natural history of benign prostatic hypertrophy
18. Comparison of testosterone, 5α‐dihydrotestosterone and 5α‐androstane‐3β‐17β‐diol metabolisms in human normal and hyperplaastic prostates
19. A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate
20. Markers of androgen action in human prostate: Potential use in clinical assessment of prostatic carcinoma
21. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate
22. Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles
23. The pathologenesis of benign prostatic hyperplasia
24. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal
25. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man
26. Comparison of androgen metabolites in benign prostatic hypertrophy (BPH) and normal prostate
27. Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate
28. Endogenous steroid levels in the human prostate from birth to old age: A comparison of normal and diseased tissue
29. Subnormal tissue 3α‐androstanediol and androsterone in prostatic hyperplasia
30. Die entstenhung der sogenannten prostatahypertrophie virchowa
31. Early phases of prostatic hyperplasia
32. Origin and evolution of benign prostatic enlargement
33. Hormonal induced morphogenesis and growth: Role of the mesenehymal‐epithelial interactions
34. Stromal‐epithelial interactions in sex differentiation
35. Antagonistic effect of androgen on prostatic cell death
36. Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model
37. Activation of programmed cell death in the rat ventral prostate after castration
38. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept
39. The effects of α‐dihydrotestosterone in the kinetics of cell proliferation in rat prostate
40. Recent advances in the cell biology of aging
41. Sex steroid imprinting of the immature prostate: Long‐term effect
42. Sex steroids imprinting and prostatic growth
43. Development of canine benign prostatic hyperplasia with age
44. Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia
45. Comparative aspect of prostatic growth and androgen metabolism with aging in the dog versus the rat
46. The induction of prostatic hypertrophy in the dog with androstanediol
47. Comparison of spontaneous and experimentally induced canine prostatic hyperplasia
48. Common characteristics of human and canine benign prostatic hyperplasia
49. Stromal‐epithelial interactions. II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyne
50. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia
51. Changes in dihydrothestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle
52. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: Characterization of nuclear salt‐resistant receptors
53. Androgen‐ and estrogen‐receptor content in spontaneous and experimentally induced canine prostatic hyperplasia
54. Hypomethylation of DNA in pathological conditions of the human prostate
55. Spontaneous benign prostatic hyperplasia in the beagle: Age‐associated changes in serum hormone levels and morphology and secretory function of the canine prostate
56. Benign prostatic hyperplasia: Gross and microscopic anatomy
57. Prostatic infarction‐role in acute urinary retention
58. The incidence of benign prostatic hypertrophy
59. Natural history of prostatic obstruction
60. Natural history of benign prostatic hypertrophy and acute urinary retention
61. The prostate and the endocrines: A control series